Flyer

Journal of Neurology and Neuroscience

  • ISSN: 2171-6625
  • Journal h-index: 18
  • Journal CiteScore: 4.35
  • Journal Impact Factor: 3.75
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Scientific Journal Impact Factor (SJIF)
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Abstract

A Case of Limbic Encephalitis: Antibody LGI1 Associated Encephalitis

Kairavi Bhardwaj, Shiv Kumar Sharma, Pandey AK and Vaishali Upadhyaya

Limbic encephalitis (LE) is a rarely encountered disease in modern clinical practice. It is basically autoimmune in nature, with its pathophysiology determined by a number of antibodies to neural surface proteins. However, 20% of cases are paraneoplastic and have a tumour source in the body which leads to limbic encephalitis secondarily. Studies have shown that VGKC complex (Voltage Gated Potassium Channels) is one of the common antibodies found in this disease and is represented by three such proteins out of which LGI1 is most prevalent in limbic encephalitis. This entity is characterized by monophasic presentation with acute or subacute onset memory loss, confusion, seizures and psychiatric symptoms. The presence of anti LGI1 antibodies in serum or CSF confirms the diagnosis. We hereby report a case of a 65 year old woman with 8 months history of peripheral neuropathy followed by memory impairment, focal seizures with behavioural and psychiatric changes. No tumour was found on imaging and the classic paraneoplastic panel was negative. However, she was found to be positive for Antibody LGI1 proving autoimmune basis of her illness which responded majorly to immuno-modulatory therapy in the form of high dose steroids.